Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Insider Sells 3,000 Shares of Stock

Key Points

• Insider Rafael Amado sold 3,000 shares of Zai Lab stock at an average price of $35.00, resulting in a total sale value of $105,000, thereby reducing his ownership by 6.64%.
• Zai Lab reported a quarterly EPS of ($0.37), meeting consensus estimates, but it had revenue of $109.98 million, which fell short of the estimated $125.66 million.
• Large investors have shown interest in Zai Lab, with 41.65% of the stock owned by institutional investors, indicating a potential vote of confidence despite recent stock fluctuations.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) insider Rafael Amado sold 3,000 shares of the company's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $35.00, for a total value of $105,000.00. Following the completion of the transaction, the insider owned 42,178 shares of the company's stock, valued at $1,476,230. The trade was a 6.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Zai Lab Stock Down 1.0%

Shares of Zai Lab stock traded down $0.35 on Tuesday, reaching $34.31. The company's stock had a trading volume of 394,193 shares, compared to its average volume of 995,971. The company has a market capitalization of $3.81 billion, a price-to-earnings ratio of -16.82 and a beta of 1.03. The firm's fifty day simple moving average is $36.70 and its two-hundred day simple moving average is $33.36. Zai Lab Limited Unsponsored ADR has a 52 week low of $16.01 and a 52 week high of $44.34.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) EPS for the quarter, hitting the consensus estimate of ($0.37). Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%. The company had revenue of $109.98 million during the quarter, compared to analyst estimates of $125.66 million. As a group, research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Institutional Investors Weigh In On Zai Lab

Large investors have recently added to or reduced their stakes in the stock. Kingsview Wealth Management LLC lifted its holdings in Zai Lab by 6.0% during the first quarter. Kingsview Wealth Management LLC now owns 9,323 shares of the company's stock worth $337,000 after buying an additional 529 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Zai Lab during the fourth quarter worth $29,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Zai Lab by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company's stock worth $1,496,000 after buying an additional 1,200 shares during the period. Walleye Capital LLC lifted its holdings in Zai Lab by 6.4% during the first quarter. Walleye Capital LLC now owns 22,276 shares of the company's stock worth $805,000 after buying an additional 1,338 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Zai Lab by 13.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 12,544 shares of the company's stock valued at $453,000 after purchasing an additional 1,483 shares during the last quarter. 41.65% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ZLAB shares. Wall Street Zen cut Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Leerink Partners set a $75.00 price objective on Zai Lab and gave the stock an "outperform" rating in a report on Monday, June 30th. Finally, Citigroup reissued a "buy" rating and issued a $69.00 target price (up previously from $66.00) on shares of Zai Lab in a research report on Monday. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $57.22.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.